Portal de Periódicos da CAPES

Prognostic and predictive factors in pancreatic cancer

2020; Impact Journals LLC; Volume: 11; Issue: 10 Linguagem: Inglês

10.18632/oncotarget.27518

1949-2553

Emanuela Dell’Aquila, Claudia Angela Maria Fulgenzi, Alessandro Minelli, Fabrizio Citarella, Marco Stellato, Francesco Pantano, Marco Russano, Maria Concetta Cursano, Andrea Napolitano, Tea Zeppola, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini,

Cancer Immunotherapy and Biomarkers

// Emanuela Dell'Aquila 1 , Claudia Angela Maria Fulgenzi 1 , Alessandro Minelli 1 , Fabrizio Citarella 1 , Marco Stellato 1 , Francesco Pantano 1 , Marco Russano 1 , Maria Concetta Cursano 1 , Andrea Napolitano 1 , Tea Zeppola 1 , Bruno Vincenzi 1 , Giuseppe Tonini 1 and Daniele Santini 1 1 Department of Medical Oncology, University Campus Bio-Medico, Rome 00128, Italy Correspondence to: Fabrizio Citarella, email: f.citarella@unicampus.it Keywords: metastatic pancreatic cancer; predictive and prognostic factors; CA19-9; gemcitabine-abraxane; FOLFIRINOX Received: January 19, 2020 Accepted: February 17, 2020 Published: March 10, 2020 ABSTRACT Pancreatic cancer is one of the leading causes of cancer death worldwide. Its high mortality rate has remained unchanged for years. Radiotherapy and surgery are considered standard treatments in early and locally advanced stages. Chemotherapy is the only option for metastatic patients. Two treatment regimens, i. e. the association of 5-fluorouracil- irinotecan-oxaliplatin (FOLFIRINOX) and the association of nab-paclitaxel with gemcitabine, have been shown to improve outcomes for metastatic pancreatic adenocarcinoma patients. However, there are not standardized predictive biomarkers able to identify patients who benefit most from treatments. CA19-9 is the most studied prognostic biomarker, its predictive role remains unclear. Other clinical, histological and molecular biomarkers are emerging in prognostic and predictive settings. The aim of this review is to provide an overview of prognostic and predictive markers used in clinical practice and to explore the most promising fields of research in terms of treatment selection and tailored therapy in pancreatic cancer.